Document is current
Any future updates will be listed below
-
Authors
Solaymani-Dodaran, Masoud
Basiri, Pouria
Moradi, Milad
Gohari, Kimiya
Sheidaei, Ali
Ahi, Mohammadreza
Ghafoori Naeeni, Farzad
Ansarifar, Akram
Rahimi, Zahra
Gholami, Fatemeh
Karimi Rahjerdi, Ahmad
Hamidi Farahani, Ramin
Naderi saffar, Kosar
Ghasemi, Soheil
Shooshtari, Ali
Honari, Mohsen
Mozafari, Ali
Khodaverdloo, Samane
Forooghizadeh, Mohsen
-
Clinical Trials BETA
Clinical trials referenced in this document:
irct20210206050259n3 at Iranian Registry of Clinical TrialsDocuments that mention this clinical trial
Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial
https://doi.org/10.1186/s12985-023-02121-z
-
Funding
Funding for this research was provided by:
Milad Daro Noor Pharmaceutical (MDNP) Company, Iran, Islamic Republic Of
- License Information
-
More Information
Article History
Received: 2 November 2022
Accepted: 8 July 2023
First Online: 18 July 2023
Declarations
:
: The clinical trial protocol was approved by the Iranian National Ethics Committee for research (approval number IR. NREC.1400.006, 31st August 2021).
: Not applicable.
: AKR, SG, AS, AM, MH, and SK are employees of Milad Daro Noor Pharmaceutical (MDNP). MSD is an Iran University of Medical Science (IUMS) employee. MSD, PB, AA, MA, ASH, ZR, FGH, and KG are members of the clinical trial center of the Iran University of Medical Science that acted as academic CRO. All other authors declare no other competing interests.
